超微脂康饮对非酒精性脂肪性肝病大鼠模型的疗效  

Efficacy of Chaowei Zhikangyin in treatment of rat model of non-alcoholic fatty liver disease

作　　者：熊焰[1] 章志娟[2] 刘鹏[1] 王雅[1] 

机构地区：[1]湖南中医药大学第一附属医院,长沙410007 [2]南昌市第九医院,江西南昌330002

出　　处：《临床肝胆病杂志》2015年第1期78-81,共4页Journal of Clinical Hepatology

基　　金：湖南省自然科学基金(12JJ6075)

摘　　要：目的观察超微脂康饮对实验性非酒精性脂肪肝(NAFLD)大鼠模型的疗效。方法 SD大鼠高脂饮食饲养6周后诱导非酒精性脂肪肝大鼠模型,肝脏病理切片证实造模成功;造模大鼠50只随机分为5组,超微脂康饮(低、中、高剂量)组给予相应剂量的超微脂康饮灌胃,壳脂胶囊组给予壳脂胶囊混悬液,模型组及空白组灌服蒸馏水,除空白组外,其余组仍予高脂饮食。6周后分别检测各组的肝功能、血脂、肝脂及肝脏组织学改变。各组之间比较采用单因素方差分析。结果超微脂康饮各组血清ALT、AST、肝组织脂质(TC、TG)等方面均优于模型组,差异均有统计学意义(P值均<0.05),超微脂康饮中,低剂量组血清TG、TC显著优于模型组,差异均有统计学意义(P值均<0.05);超微脂康饮各组血清ALT、AST、肝组织TC与壳脂胶囊组比差差异无统计学意义(P值均>0.05)。模型组及超微脂康饮各组均存在不同程度的肝脏炎症活动度,但与模型组比较,超微脂康饮各组、壳脂胶囊组大鼠的肝脏炎症活动度均有不同程度的改善(P值均<0.05),而壳脂胶囊组较超微脂康饮各组改善稍明显(P值均<0.05)。结论超微脂康饮能改善NAFLD大鼠肝功能、降低血脂、抑制肝脏炎症,整体疗效与壳脂胶囊相当,对非酒精性脂肪肝具有一定疗效。Objective To observe the efficacy of Chaowei Zhikangyin in the treatment of the rat model of non-alcoholic fatty liver disease （NAFLD）.Methods A rat model of NAFLD was established by feeding 50 Sprague-Dawley rats with high-fat diet for 6 weeks and was confirmed by liver pathological examination.Then,the model rats were randomly divided into five groups：low-,medium-,and high-dose Chaowei Zhikangyin groups （given Chaowei Zhikangyin by gavage）,Kezhi capsule treatment group （given a suspension of Kezhi cap-sules）,and model group （orally given distilled water）.In addition,control rats were fed with normal diet and then treated with distilled wa-ter.Six weeks later,the liver function,blood lipids,liver lipids,and liver histology were examined.Results All Chaowei Zhikangyin groups were superior to the model group in terms of alanine aminotransferase,aspartate aminotransferase,total cholesterol （TC）,and tri-glyceride （TG）in serum and TC and TG in liver tissues （P〈0.05）,but there were no significant differences between these Chaowei Zhi-kangyin groups and Kezhi capsule treatment group （P〉0.05）.Different degrees of liver inflammation was observed in the model group and Chaowei Zhikangyin groups;however,the Chaowei Zhikangyin groups and Kezhi capsule treatment group had reduced liver inflammation compared with the model group （P〈0.05）,and the Kezhi capsule treatment group showed a significantly more improvement than these Cha-owei Zhikangyin groups （P〈0.05）.Conclusion Chaowei Zhikangyin can improve liver function,reduce blood lipids,and inhibit liver in-flammation in rats with NAFLD,and it has comparable efficacy to Kezhi capsules.This therapy can be used for treating NAFLD.

关 键 词：脂肪肝 超微脂康饮 大鼠 sprague-dawley 

分 类 号：R575.5[医药卫生—消化系统]